Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

چکیده اصلی

OBJECTIVE: Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study aims to assess the real-world effectiveness and safety of Brentuximab vedotin (BV)-containing regimens compared to non-BV regimens in relapsed or refractory classical Hodgkin lymphoma (cHL) in Saudi Arabia. METHODS: A retrospective, multicenter cohort study was conducted including 93 adult patients with relapsed or refractory cHL in Saudi Arabia between 2016 and 2021. Patients were categorized into a BV-containing group (n = 61) and a control group (n = 32). The outcomes were overall response rate (ORR), complete response (CR), event-free survival (EFS), and post-chemotherapy complications. RESULTS: = The BV group showed a higher ORR compared to the non-BV group (82.5% vs. 76.9%), although this difference was not statistically significant (adjusted odds ratio [aOR] = 9.09; 95% CI = 0.67-122.57; P = 0.10). CR rates were comparable between the two groups, at 59.6% in the BV group vs. 61.5% in the control group (aOR = 1.86; 95% CI = 0.24-14.46; P = 0.55). EFS was significantly longer in the BV group compared with the control group in the crude analysis (22.5 vs. 11.2 months; P = 0.03); however, this finding did not reach statistical significance in the regression analysis (beta coefficient = 7.04; 95% CI = -2.96 to 17.03; P = 0.18). Post-chemotherapy complications were comparable and not statistically significant across both groups. CONCLUSION: The research indicates that BV may offer a potential clinical advantage for patients with relapsed or refractory cHL. To validate these findings and optimize treatment strategies for this population, larger long-term studies with expanded patient cohorts are required.

متن کامل اصلی